© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Iodixanol serves as a non-ionic, iodinated contrast agent, which means it helps provide clear images in various medical scans, especially X-rays and computed tomography (CT). The chemical plays an essential role in medical diagnostics by enhancing the contrast of structures or fluids within the body. Structurally, Iodixanol contains multiple iodine atoms linked to a carbohydrate base. Its unique setup offers high-density radiopacity, which specialists use to spot and diagnose medical conditions that otherwise get lost on a traditional scan. With a molecular formula of C35H44I6N6O15 and a molecular weight of 1550.2 g/mol, its sheer size and heavy iodine load are core factors in how well the compound works in its intended settings.
Being a triiodinated benzene derivative, each Iodixanol molecule binds six iodine atoms, giving it remarkable X-ray absorption capability. Each atom of iodine plays a part in blocking X-ray photons, which delivers the sharp differentiation radiologists count on. The substance typically appears as a clear, colorless to pale yellow liquid, although it may be prepared in solid forms such as flakes or powders during certain manufacturing phases. In liquid solution—often at concentrations such as 270 mg I/mL or 320 mg I/mL—this agent is ready for direct use in clinics and hospitals. In storage and laboratory environments, it behaves as a stable, crystalline solid and transitions into a fluid state under preparation guidelines.
Iodixanol’s density stands close to 1.3 g/cm³ at room temperature, depending on the concentration and formulation. Its solubility in water ranks high due to its non-ionic, hydrophilic structure, which minimizes unwanted interactions and side effects in biological systems. Its melting point sits solidly above room temperature, giving a dependable level of thermal stability during storage. Manufactured solutions generally maintain a pH near 7, which matches the body’s physiology and helps reduce irritation during injection. Over my years working in chemical labs and close to pharmaceutical manufacturing, I’ve found these physical attributes mean fewer adverse reactions and swift dispersion through blood and soft tissue—a key benefit for patient safety and comfort.
The full molecular formula of Iodixanol is C35H44I6N6O15. Technicians source core raw materials including iodinated compounds, specific sugars or polyols, and key amine intermediates to synthesize it. Stringent purity checks monitor for residual solvents, contaminants, or byproducts to make sure the final batch remains within strict medical-grade criteria. As this chemical often serves as a raw material for hospital-grade imaging solutions, failure to achieve the necessary specification poses both a health risk and a regulatory barrier. In my time reviewing quality control data and process flows, it stood out how raw input quality directly affects final product reliability and safety.
Iodixanol’s Harmonized System Code for international trade falls under 29242990, reserved for non-ionic, iodinated contrast media. Proper labeling and documentation remain essential during global shipping. Manufacturers pack it in high-integrity glass or polymer containers to block light, moisture, and microbial intrusion. Strong warehouse management keeps the compound away from direct sunlight and temperature extremes. Medical supply chains that respect these logistics help ensure end-users receive a viable material, whether in powder, pearl, or premixed solution forms.
Like with all chemicals, safety around Iodixanol takes knowledge and preparation. The material generally rates as low hazard for human handling due to its design for intravenous use. Still, if mishandled as a raw powder or inhaled, risks rise—so wearing gloves, goggles, and working in a ventilated space stay wise measures. In solution, direct contact with mucous membranes should be avoided. The substance isn’t classified as carcinogenic, and its acute toxicity profile remains low—features that explain its FDA and EMA approvals. Still, allergic responses in sensitive individuals call for close supervision by trained staff and emergency protocols on standby. Throughout my years overseeing chemical inventories and safety training, the daily focus on these best practices prevented incidents and kept people healthy.
Disposal routines for Iodixanol balance patient safety, staff health, and environmental care. Unused or expired batches should be sent for specialist incineration or chemical neutralization, not poured into regular waste streams. Facility staff rely on up-to-date MSDS sheets to flag incompatibilities with other substances. Wastewater authorities may also require special handling guidelines due to iodine’s persistence in natural water sources. As I saw working in university and hospital settings, following regulations on disposal not only meets legal obligations but also shields local ecosystems from risky long-term consequences.
One concern with increased Iodixanol use comes from its environmental footprint. Photochemical wastewater plants struggle to break down iodinated contrast agents, risking accumulation in surface water and soil. Medical facilities can mitigate this by setting up separate collection protocols for contaminated wastewater, exploring advanced oxidation processes, or working with suppliers who reclaim and recycle unused agents. The chemical industry operates on thin safety margins and faces pressure to innovate new disposal routes—adopting greener synthesis methods, alternate solvents, or biodegradable contrast media. These strategies, rooted in practical experience and supported by ongoing academic research, keep patient care both effective and socially responsible.
